<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8066">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01694004</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #121111</org_study_id>
    <secondary_id>P30DK058404</secondary_id>
    <nct_id>NCT01694004</nct_id>
  </id_info>
  <brief_title>Nutrient Sensing in the Duodenum</brief_title>
  <official_title>Duodenal Lipid Sensing and Nutrient Absorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary studies in humans suggest that the presence of lipids in the gut can modify
      glucose absorption. The overall hypothesis of this proposal is that long chain fatty acid
      sensing in the duodenum has a significant role in modifying nutrient (glucose and amino
      acid) absorption from the GI tract through a gut-brain-gut axis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving
      intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid tracers
      and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will
      allow the investigators to determine if LCFA can alter nutrient absorption and glucose and
      amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve
      terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of
      glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK,
      GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs)
      will be measured during all infusion periods.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Nutrient Absorption</measure>
    <time_frame>2 yrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>Stable isotope tracers (glucose or amino acid) will be administered intravenously (IV) and intraduodenally (ID) and tracer rate of appearance in the plasma will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substrate Oxidation</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oxidation of intraduodenally administered glucose or amino acid will be determined by the amount of 13C recovered from expired air.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Hormone Levels</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma levels of gut hormones will be measured by standard RIA or ELISA assays</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bioactive Lipids</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma levels of N-acyl phosphatidylethanolamines (NAPES)will be measured by LC-MS</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>The Effect of LCFA on Nutrient Absorption</condition>
  <arm_group>
    <arm_group_label>LCFA effects on glucose and amino acid absorption</arm_group_label>
    <description>The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placement of naso-duodenal tube and infusions</intervention_name>
    <arm_group_label>LCFA effects on glucose and amino acid absorption</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Residents within and near Nashville, TN
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI = 19-27 kg/m2

          -  30-55 years of age

        Exclusion Criteria:

          -  Contraindication for nasal tube placement (e.g. deviated septum, prior upper
             gastrointestinal bleed, or history of easy bleeding)

          -  Prior gastric or intestinal surgery or pancreas resection

          -  Females with a positive pregnancy test

          -  Known history of intestinal diseases including (but not limited to) inflammatory
             bowel disease (e.g. ulcerative colitis, Crohn's disease), celiac sprue, Barrett's
             esophagus

          -  Type 1 or type 2 diabetes

          -  Gastroenteritis (diarrhea and/or vomiting) or constipation within the past week
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>September 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Robyn Tamboli</investigator_full_name>
    <investigator_title>Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Nutrient absorption</keyword>
  <keyword>Duodenal feeding tube</keyword>
  <keyword>Gut-brain-gut axis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
